dorsaVi Accelerates US PT Rollout and Push Into AI and Neuromorphic Tech

dorsaVi Limited ( (AU:DVL) ) has provided an update.

dorsaVi reported a strong December quarter, with cash receipts from customers rising 50% quarter-on-quarter to $280,000, supported by rapid commercial scaling in the US physical therapy market where more than 100 new PT sites were onboarded under its five-year sales agreement with Select Medical and other major groups. The company advanced a strategic transformation toward high-value AI, robotics and neuromorphic technology, completing a leadership transition with the appointment of a new Group CEO and Executive Chairman, securing exclusive Process-In-Memory IP from Technion, launching work on 22nm RRAM integration, and ending the period with a $4.95 million cash balance, while growing its influence in sports medicine as more than 60 surgeons now prescribe its AMI assessments, reinforcing its bid to become a standard for objective return-to-play protocols.

The most recent analyst rating on (AU:DVL) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.

More about dorsaVi Limited

dorsaVi Limited (ASX:DVL) is an Australian technology company focused on sensor-based movement analysis and data-driven clinical assessment tools, primarily serving the US physical therapy and sports medicine markets. Its products, including the ViMove+ platform and the Athletic Movement Index (AMI), are used by large PT networks and elite sports organisations to deliver objective, metrics-based evaluation and rehabilitation, positioning the company at the intersection of healthcare, sports performance, and emerging AI and robotics technologies.

Average Trading Volume: 3,305,314

Technical Sentiment Signal: Buy

Current Market Cap: A$46.24M

For detailed information about DVL stock, go to TipRanks’ Stock Analysis page.